Company: DMAAR
Filing Date: 2025-01-22
Form Type: POS AM
Source: 0001213900-25-005176
Chunk: 202

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-22
Form: POS AM
Chunk 202
---
 (ii) vote any public shares they may own at the applicable time in favor of our initial business combination or (iii) refrain from exercising their right to redeem their public shares at the time of our initial business combination. The non -managingsponsor investors will have the same rights to the funds held in the trust account with respect to the public shares comprising part of the units they may purchase in this offering as the rights afforded to our other public shareholders. However, if the non -managingsponsor investors purchase all of the units for which they have expressed to us an interest in purchasing or otherwise hold a substantial number of our units, then the non -managingsponsor investors will potentially have different interests than our other public shareholders in approving our initial business combination and otherwise exercising their rights as public shareholders because of their indirect ownership of founder shares as further discussed in this prospectus. There can be no assurance that the non -managingsponsor investors will acquire any units, either directly or indirectly, in this offering, or as to the amount of the units these investors will retain, if any, prior to or upon the consummation of our initial business combination. Because these expressions of interest are not binding agreements or commitments to purchase, non -managingsponsor investors may determine to purchase fewer units in this offering, more units in this offering, or none at all. In addition, the underwriters have full discretion to allocate the units to investors and may determine to sell fewer units to the non -managingsponsor investors, or none at all, and the purchase of the non -managingsponsor membership interests is not contingent upon the participation in this offering or vice -versa. Depending on how many units are purchased by the non -managingsponsor investors, the post -offeringtrading volume, volatility and liquidity of our securities may be reduced relative to what they would 129 have been had the units been more widely offered and sold to other public investors. We do not expect any purchase of units by the non -managingsponsor investors to negatively impact our ability to meet Nasdaq listing eligibility requirements. The underwriter will receive the same upfront discounts and commissions and deferred underwriting commissions on units purchased by the non -managingsponsor investors, if any, as it will on the other units sold to the public in this offering. In the event that the non -managingsponsor investors purchase the number of units in which they have expressed an interest (either in this offering or after) and vote